11/23/2015
`Federal Register, Volume 62 Issue 53 (Wednesday, March 19, 1997)
`[Federal Register Volume 62, Number 53 (Wednesday, March 19, 1997)]
`[Notices]
`[Page 13158]
`From the Federal Register Online via the Government Printing Office [www.gpo.gov]
`[FR Doc No: 97-7017]
`
`-----------------------------------------------------------------------
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`Meeting Announcement
`
` The National Center for Environmental Health (NCEH) of the Centers
`for Disease Control and Prevention (CDC) announces the following
`meeting:
`
` Name: Preventing Birth Defects Due to Thalidomide Exposure.
` Time and date: 8 a.m.-5 p.m., March 26, 1997.
` Place: Sheraton Colony Square Hotel, 188 14th Street, NE,
`Atlanta, Georgia 30361.
` Status: Open to the public, limited only by the space available.
`The meeting room accommodates approximately 75 people. Registration
`is not required.
` Purpose: The meeting will enable academic and public health
`professionals to discuss strategies to prevent birth defects due to
`exposure to thalidomide and other human teratogens. Thalidomide, a
`potent human teratogen, is now available as an investigational drug
`in the USA. Although the drug is currently being considered for
`approval only for the treatment of leprosy, its potential
`applications appear to be numerous. This meeting will bring together
`leaders from the fields of birth defects research, clinical
`practice, bioethics, and public health to review existing strategies
`for limiting intrauterine exposure to human teratogens, and to
`discuss and provide individual input on new approaches for
`preventing birth defects due to future teratogens such as
`thalidomide.
` Matters to be discussed: Agenda items will include presentations
`on the following topics: (1) Assessment of the Accutane Pregnancy
`Prevention Program, (2) use and limitations of drug registries, (3)
`contraception efficacy, (4) ethical issues on teratogen exposure,
`and (5) measures to assure appropriate use of pharmaceuticals. Group
`discussions on strategies for health care provider education,
`patient education, and appropriate use of pharmaceuticals will
`follow the presentations. Written materials may be submitted to CDC
`until March 21, 1997, for distribution to meeting participants.
` Agenda items are subject to change as priorities dictate.
` FOR FURTHER INFORMATION CONTACT: Dwight Jones, Division of Birth
`Defects and Developmental Disabilities, NCEH, CDC, 4770 Buford
`Highway, NE, M/S F-45, Atlanta, Georgia 30341-3724, telephone 770/
`488-7160, Fax 770/488-7197.
`
` Dated: March 13, 1997.
`Carolyn J. Russell,
`Director, Management Analysis and Services Office, Centers for Disease
`Control and Prevention (CDC).
`[FR Doc. 97-7017 Filed 3-18-97; 8:45 am]
`BILLING CODE 4163-18-P
`
`http://www.gpo.gov/fdsys/pkg/FR-1997-03-19/html/97-7017.htm
`
`1/2
`
`CFAD VI 1076 - 0001
`CFAD VI v. CELGENE
`IPR2015-01102
`
`

`
`11/23/2015
`
`Federal Register, Volume 62 Issue 53 (Wednesday, March 19, 1997)
`
`http://www.gpo.gov/fdsys/pkg/FR-1997-03-19/html/97-7017.htm
`
`2/2
`
`CFAD VI 1076 - 0002